PRF Technologies PRFX
NASDAQ PRFX
$1.00 0.00 (-0.29%)
At close: Aug 21, 2026 · 4:00 PM EDT

PRF Technologies (PRFX) Net Equity Issued and Repurchased (2021 - 2023)

PRF Technologies' (PRFX) quarterly Net Equity Issued and Repurchased came in at -$1.7 million in Q4 2023, down 200.0% on a QoQ basis from $1.7 million in Q3 2023.

PRF Technologies (PRFX) Net Equity Issued and Repurchased (2021 - 2023) Analysis & Trends

PRF Technologies (PRFX) has 2 years of Net Equity Issued and Repurchased data on file, last reported at -$1.7 million in Q4 2023.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$1.7 million in Q4 2023, while the trailing twelve-month figure through Sep 2023 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $4.0 million, up 196.3% from the prior year.
  • Net Equity Issued and Repurchased retreated to -$1.7 million in Q4 2023, from $1.7 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $6.0 million in Q1 2021 to a low of -$1.7 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Haleon 44.51 Bn 43.55 Bn - -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn -
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn -
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn -
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn -
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn 700,000.00
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn 84.80 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn -
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn - -
10 PRF Technologies 647,973.00 -3.49 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -1.70 Mn
Dec 31, 2023 -1.70 Mn
Sep 30, 2023 1.70 Mn
Sep 30, 2023 1.70 Mn
Dec 31, 2021 446,000.00
Dec 31, 2021 446,000.00
Sep 30, 2021 -446,000.00
Sep 30, 2021 -446,000.00
Mar 31, 2021 6.00 Mn
Mar 31, 2021 6.00 Mn